Agenta's technologies capitalize on variations of the important biomolecules called proteoglycans, a class of molecules that can promote healing through a variety of known mechanisms. As therapeutics, they can be applied to bone and skin, or serve as coatings for various devices. It is Agenta's mission to be the world provider in manipulating proteoglycans for therapeutic use.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells

CellSignals applies its technology in chiral synthesis to develop lipid mediators pertinent to intracellular signal transduction and cancer biology. Currently CellSignals' product line has grown to more than 40 chemicals covering a variety of inositol polyphosphates and phosphatidylinositol polyphosphates. CellSignals is actively developing small-molecules, orally bio-available therapeutics for the treatments of breast, skin cancers, and leukemia.

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.

Femta is developing a new generation of antibody therapeutics for major disease indications.